437. Identification of Brain/Behavior-Based Pro-Cognitive  Pharmacodynamic Effects for ALTO-101 in Healthy Volunteers: Results From a Randomized, Double-Blind Phase 1 Study

ALTO-101 is a selective brain-penetrant PDE4 inhibitor shown to increase cAMP levels in brain regions critical for cognition, memory, and mood and may have potential as a novel treatment for neuropsychiatric disorders, including schizophrenia. Here we sought to identify pharmacodynamic (PD) biomarkers for ALTO-101 that could indicate its effects on cognitive processes.

Source: Biological Psychiatry - April 29, 2024 Category: Psychiatry Authors: Akshay Sujatha Ravindran, Guhan Sundar, Samantha Goncalves, Chao Wang, Li Shen, Maimon Rose, Joshua Jordan, Nicholas Cooper, Sebastian Marquez, Faizan Badami, Wei Wu, Amit Etkin, Adam Savitz Source Type: research